SEPNSepterna, Inc.
$50.77+146% 1Y
$50.77
$18.1052 weeks$50.77
Latest close: a new 52-week highNov 9, 2026what changed →
The business
How SEPN's business earns
Septerna, Inc. keeps −76% of every revenue dollar as operating profit, against −61% for the median Biotechnology name.
−76%
Operating margin · Biotechnology median −61% · 12 months to Sep 30, 2026
- Share count, year on year
- +2.9%
Share count, year on year · more shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2023 | 1374% |
| FY2024 | −7518% |
| FY2025 | −149% |
Details›
- Operating margin12 months to Sep 30, 2026
- −76%
- Net margin12 months to Sep 30, 2026
- −61%
- Free cash flow margin
- −81%
- R&D as % of revenue
- 138%
- Revenue, trailing twelve months
- $96M
- Free cash flow, trailing twelve months
- −$78M
- Net income, trailing twelve months
- −$59M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry